Business Wire

Mary Kay Inc. Continues Its Support of Women’s Empowerment at the International Women’s Forum TIME’S UP Virtual Conference

19.5.2020 17:53:00 EEST | Business Wire | Press release

Share

Mary Kay Inc. continues its support of female entrepreneurship, empowerment and thought leadership as a premier sponsor for the 2020 International Women's Forum (IWF) Virtual Cornerstone Conference. Originally scheduled to take place May 13-15, in London, the conference has shifted to a digital format due to the COVID-19 pandemic; much of the same great content and speakers will be broadcast globally in a series of virtual sessions shared weekly at https://www.iwforum.org/.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005709/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Carolyn Passey, General Manager, Mary Kay United Kingdom & Ireland (Photo: Mary Kay Inc.)

On May 21, Mary Kay will participate in a virtual session entitled “A Conversation with TIME’S UP UK” discussing important issues such as #MeToo and how the ensuing TIME’S UP movement has led to re-thinking women’s safety on film and television sets, as well as other industries around the world. Carolyn Passey, General Manager of Mary Kay UK and Ireland, will open the session focusing on changes TIME’S UP UK is seeking to implement, navigating the line between personal and professional, and aiding those who frequently find themselves vulnerable and exploited while filming.

“At Mary Kay, we advocate for women’s empowerment and gender equality and we partner with organizations whose mission is to do the same,” said Passey. “Today, as the COVID-19 crisis is exacerbating women's vulnerabilities and gender inequality1, we know trust and safety are more critical than ever for women to thrive. The workplace should be a safe and dignified place for all of us. How can we ensure—and demand—this happens? I look forward to the discussion on the topic with thought leaders from around the world.”

Speakers at the session include:

  • Dame Heather Rabbatts, TIME’S UP UK Chair Managing Director of Cove Pictures; Chair of Soho Theatre and non-executive board member for Arts Alliance.
  • Ita O’Brien, the UK’s leading Intimacy Coordinator and founder of Intimacy on Set, her company through which she has been developing best practices regarding intimacy and nudity in film, television and theatre and through which she trains Intimacy Coordinators all over the world.

“Now, more than ever, it is crucial to continue the conversation around safe and equal working conditions for women within the entertainment industry and beyond,” said Stephanie O’Keefe, CEO of IWF. “As the world develops a new way to work in the context of COVID-19, I am hopeful that there will be strategies in place to ensure women can re-enter the physical workplace with confidence they will be safe and treated equally. Mary Kay is a long-time supporter of gender equality, and we are thrilled to continue this fight with them to ensure a more gender-equal world.”

A link to watch the event will be available on the IWF website and its YouTube page May 26: https://www.youtube.com/channel/UCdLPNS7ai1_XHaqgEnhEjtg

1 United Nations Secretary-General’s Policy Brief on The Impact of COVID-19 on Women, April 9, 2020
https://www.un.org/sites/un2.un.org/files/policy_brief_on_covid_impact_on_women_9_apr_2020_updated.pdf
and - Blog article by United Nations Foundation, Blog article from Michelle Milford Morse and Grace Anderson, April 14, 2020
https://unfoundation.org/blog/post/shadow-pandemic-how-covid19-crisis-exacerbating-gender-inequality/

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.

About International Women’s Forum (IWF) and the Leadership Foundation

IWF is an invitation-only membership organization of more than 7,000 diverse and accomplished women from 33 nations on six continents. IWF advances women’s leadership and champions equality worldwide by connecting accomplished women both globally and locally. Members include Fortune 500 executives, government leaders from the local to sovereign level, international nonprofit leaders, and luminaries from the academy, arts and sciences. For more information, please visit www.iwforum.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye